Bank of New York Mellon Corp Invests $5.67 Million in Artivion, Inc. $AORT

Bank of New York Mellon Corp bought a new position in shares of Artivion, Inc. (NYSE:AORT - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 252,386 shares of the company's stock, valued at approximately $5,671,000. Bank of New York Mellon Corp owned about 0.52% of Artivion as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of AORT. Verition Fund Management LLC grew its position in shares of Artivion by 1.6% during the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company's stock worth $716,000 after buying an additional 274 shares during the period. Entropy Technologies LP raised its holdings in Artivion by 6.0% in the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company's stock worth $251,000 after purchasing an additional 310 shares during the period. Rockefeller Capital Management L.P. boosted its position in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock worth $30,000 after purchasing an additional 399 shares in the last quarter. Arizona State Retirement System grew its holdings in shares of Artivion by 4.6% in the 4th quarter. Arizona State Retirement System now owns 11,235 shares of the company's stock valued at $512,000 after buying an additional 494 shares during the period. Finally, Amundi increased its position in shares of Artivion by 7.5% in the 1st quarter. Amundi now owns 7,186 shares of the company's stock valued at $263,000 after buying an additional 501 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Stifel Nicolaus set a $45.00 target price on Artivion in a research note on Monday, June 1st. Weiss Ratings lowered Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Tuesday, August 11th. Needham & Company LLC reiterated a "buy" rating and set a $44.00 price objective on shares of Artivion in a report on Monday, July 20th. Canaccord Genuity Group boosted their price objective on Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Finally, Citigroup reissued a "market outperform" rating on shares of Artivion in a research note on Tuesday, July 21st. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Artivion Stock Performance

NYSE:AORT opened at $25.59 on Friday. The stock has a 50 day simple moving average of $26.09 and a 200 day simple moving average of $29.21. The stock has a market cap of $1.25 billion, a P/E ratio of -365.52 and a beta of 1.25. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The company had revenue of $125.76 million for the quarter, compared to analysts' expectations of $119.99 million. Research analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO James P. Mackin sold 70,000 shares of Artivion stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the sale, the chief executive officer directly owned 877,275 shares of the company's stock, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the transaction, the senior vice president owned 184,118 shares of the company's stock, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 122,981 shares of company stock worth $3,181,531 in the last three months. 6.30% of the stock is owned by corporate insiders.

Artivion Company Profile

Artivion, Inc NYSE: AORT is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source